<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298324</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2005-006178-86</org_study_id>
    <secondary_id>EBMT-LE-0601</secondary_id>
    <nct_id>NCT00298324</nct_id>
  </id_info>
  <brief_title>Myfortic - Treatment for Extensive cGvHD</brief_title>
  <official_title>A Randomized Double Blinded Placebo-Controlled Phase III Trial Comparing Cyclosporine Plus Steroids With or Without Myfortic as Primary Treatment for Extensive Chronic Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the response to treatment for extensive&#xD;
      chronic Graft versus Host Disease (cGvHD)is improved with the addition of myfortic alongside&#xD;
      cyclosporine A and prednisone, compared to the reference treatment of cyclosporine A and&#xD;
      prednisone alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical trial is a European, multi-center, randomized, double blinded&#xD;
      placebo-controlled trial comparing CsA+PDN+MPA versus the reference treatment of CsA+PDN&#xD;
      alone + placebo, in patients with extensive chronic GvHD. Randomization will be stratified&#xD;
      according to:&#xD;
&#xD;
        -  Platelet number (low versus high risk)&#xD;
&#xD;
        -  Source of transplantable cells (marrow versus PBSC versus cord blood)&#xD;
&#xD;
      Patients not in progression at 6 weeks post randomization (progression defined as primary&#xD;
      failure) will be evaluated for remission (complete or partial) at 3, 6, 9, &amp; 12 months post&#xD;
      randomization&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow accrual&#xD;
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To test whether the addition of Myfortic improves the efficacy of prednisone plus cyclosporine for treatment of newly diagnosed chronic GvHD, as defined by the proportion of patients with efficacy success at 1 year after enrollment.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The hazard rates of efficacy success between the two arms. Loss of donor chimerism or recurrent malignancy before secondary systemic therapy and before discontinuation of all immunosuppressive meds will be treated as competing risks.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>efficacy failure, and treatment failure defined as efficacy failure or premature discontinuation of study-drug administration due to toxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival without recurrent malignancy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of secondary systemic treatment for cGvHD before recurrent malignancy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the cumulative incidence of death without recurrent or malignancy</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Myfortic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive Myfortic + Prednisone + Cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care/ Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic</intervention_name>
    <description>1440mg twice daily</description>
    <arm_group_label>Myfortic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone and Cyclosporine</intervention_name>
    <description>Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response</description>
    <arm_group_label>Standard Care/ Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 60&#xD;
&#xD;
          -  Any primary diagnosis requiring treatment by hematopoietic stem cell transplantation&#xD;
&#xD;
          -  Recipient of a single allogeneic stem cell transplant (bone marrow or peripheral blood&#xD;
             stem cells, or cord blood) minimum 80 days ago&#xD;
&#xD;
          -  Received a graft from a related or an unrelated donor&#xD;
&#xD;
          -  Conditioning regimen: Myeloablative or non-myeloablative&#xD;
&#xD;
          -  Patients suffering a first episode of extensive chronic GvHD, without recurrent&#xD;
             disease&#xD;
&#xD;
          -  The diagnosis of chronic GvHD requires the following:&#xD;
&#xD;
               -  Distinction from acute GvHD&#xD;
&#xD;
               -  Presence of at least one diagnostic clinical sign of chronic GvHD or presence of&#xD;
                  at least one distinctive sign confirmed by pertinent biopsy or other relevant&#xD;
                  diagnostic tests&#xD;
&#xD;
               -  Exclusion of other possible diagnoses&#xD;
&#xD;
          -  Receiving a standard prophylaxis regimen for acute GvHD: CsA plus methotrexate, or&#xD;
             CSA+MMF for NMA, or a T-cell depleted transplant&#xD;
&#xD;
          -  Patient gives written informed consent prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient age less than 18 years or over 60 years.&#xD;
&#xD;
          -  GvHD prophylaxis by tacrolimus plus methotrexate&#xD;
&#xD;
          -  Delayed onset acute GvHD following NMA or DLI&#xD;
&#xD;
          -  Second allogeneic stem cell transplant&#xD;
&#xD;
          -  Not the first episode of chronic GvHD needing systemic immunosuppressive therapy.&#xD;
&#xD;
          -  Limited chronic GvHD (Seattle criteria, see Appendix 1)&#xD;
&#xD;
          -  Uncontrolled systemic infection which in the opinion of the investigator is associated&#xD;
             with an increased risk of the patient's death within 1 week of randomization&#xD;
&#xD;
          -  In the opinion of the investigator, if the patient has significant medical or&#xD;
             psychosocial problems or unstable disease status&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Known hypersensitivity to mycophenolic acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gérard Socié</last_name>
    <role>Study Chair</role>
    <affiliation>Hôptial St Louis, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital St. Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Maastricht</city>
        <zip>6202</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <zip>06260</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://ebmt.org</url>
    <description>sponsor's website</description>
  </link>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>March 1, 2006</study_first_submitted>
  <study_first_submitted_qc>March 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2006</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Ruzena Uddin</name_title>
    <organization>EBMT</organization>
  </responsible_party>
  <keyword>GvHD</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>extensive</keyword>
  <keyword>myfortic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

